Pluristem Therapeutics Inc (PSTI)

[lbman]

more upgrades:

"A pair of upbeat commentaries from analysts is sending shares of stem-cell company Pluristem Therapeutics Inc. higher premarket. Oppenheimer starts coverage with a stock-investment rating of outperform, noting upbeat study data. Pluristem is developing placenta-based stem-cell therapies which “can be administered to the patient immediately by the treating physician” instead of cell harvesting, processing and reinfusion. And Needham says Pluristem has enough cash to last it through 2013 and that it is “considering pharma partnerships…which may provide further capital infusion.” Pluristem, already up 79% this year amid the study data, adds another 11% to $2.85."

http://blogs.wsj.com/marketbeat/2011/05/17/stocks-to-watch-h-p-wal-mart-and-more/?mod=yahoo_hs